Magellan Rx Management saw a significant shift in utilization from Janssen Biotech, Inc.’s Remicade (infliximab) to biosimilars after it implemented a comprehensive utilization management (UM) program, resulting in 34% drug cost savings, the PBM reported.
- Datapoint, Medicare and Medicaid
- Abstract, Drug Benefits
- People on the Move
- Medicare and Medicaid
- Datapoint, Drug Benefits